FEATURESMobile Health in Adherence to Oral Anticancer Drugs A Scoping ReviewGambalunga, Francesca MSc, RN; Iacorossi, Laura PhD, MSc, RN; Notarnicola, Ippolito PhD, MSc, RN; Serra, Valeria RN; Piredda, Michela PhD, MSc, RN; De Marinis, Maria Grazia RN, ProfAuthor Information Author Affiliations: Department of Health Professions (DAPS), University Hospital “Policlinico Umberto I” (Ms Gambalunga); IRCCS “Regina Elena” National Cancer Institute (Dr Iacorossi and Ms Serra); Centre of Excellence for Nursing Scholarship OPI Rome Italy (Dr Notarnicola); and Research Unit Nursing Science, Campus Bio-Medico of Rome University (Drs Piredda and De Marinis), Rome, Italy. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Corresponding author: Laura Iacorossi, PhD, MSc, RN, IRCCS “Regina Elena” National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy ([email protected]). Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.cinjournal.com). CIN: Computers, Informatics, Nursing: January 2021 - Volume 39 - Issue 1 - p 17-23 doi: 10.1097/CIN.0000000000000643 Buy SDC Take the CE Test Metrics Abstract In oncology, adherence to oral antineoplastic medication is a key element of treatment, on which the success of any therapeutic intervention depends. Given their widespread use in clinical practice, it is important to identify tools that can facilitate the monitoring and self-management of the patient at home, to avoid the consequences of employing ineffective treatment. One of the tools available today to take action on this phenomenon is mobile health technology. The aim of this review is to describe published studies relating to the use of mobile health to promote adherence to oral antineoplastic medication. This scoping review was conducted using the framework proposed by Arksey and O'Malley, adapted according to Levac et al. Of 1320 articles identified, only seven met the eligibility criteria and therefore were included in the review. All seven articles involved the use of digital means to measure adherence to treatment, patient satisfaction, acceptability and feasibility of the digital means used, and presence of symptoms, but not the effectiveness of the digital instrument used. In conclusion, the use of digital means to assist adherence of cancer patients to oral antineoplastic medication is widely recognized, but its effectiveness in clinical practice is poorly supported by the nature of the published studies. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.